Neuroendocrine Tumors
📧 Sign up to get email alerts when something new happens for Neuroendocrine Tumors.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-05-06Clinical Trial Update: Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis
This is a retrospective analysis using 18F-DOPA PET/CT to assess heterogeneity in metastatic neuroendocrine tumors.
-
CLINICAL_TRIALS trial_result · 2024-05-06Clinical Trial Update: The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
This entry notes the completion of a clinical trial exploring the metabolic profile of neuroendocrine tumors under the Indol Profile program…
-
CLINICAL_TRIALS trial_result · 2024-01-09Clinical Trial Update: Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors [Phase 2]
Phase 2 trial evaluating nivolumab with ipilimumab in neuroendocrine tumors (including carcinoid) has been terminated.
-
CLINICAL_TRIALS research · 2023-12-05Clinical Trial Update: 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating 68Ga-DOTA-MGS5 PET/CT imaging in patients with advanced neuroendocrine tumors has completed.
-
CLINICAL_TRIALS trial_result · 2023-11-22Clinical Trial Update: Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms [Phase 2]
Phase 2 clinical trial investigating dual 64Cu-DOTATATE and 18F-FDG PET/CT imaging for neuroendocrine neoplasms.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-07-19Clinical Trial Update: Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs [Phase 1, Phase 2]
Phase 1/Phase 2 trial evaluating safety and preliminary efficacy of 177Lu-OPS201 in neuroendocrine tumors was terminated, with results poste…
-
CLINICAL_TRIALS trial_result · 2023-06-27Clinical Trial Update: Telotristat With Lutathera in Neuroendocrine Tumors [Phase 2]
Phase 2 trial investigating telotristat with Lutathera in neuroendocrine tumors was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2023-04-03Clinical Trial Update: Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors [Phase 2, Phase 3]
Phase 2/3 clinical trial update evaluating safety and efficacy of In-111 Pentetreotide for neuroendocrine tumors has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-30Clinical Trial Update: Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors [Phase 3]
Phase III study results for surufatinib in advanced extrapancreatic neuroendocrine tumors have been completed.
-
CLINICAL_TRIALS trial_result · 2023-03-20Clinical Trial Update: 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms [Phase 2]
Phase 2 clinical trial update for 177Lu-DOTA-octreotate therapy in neuroendocrine tumors has completed.
-
CLINICAL_TRIALS trial_result · 2023-02-09Clinical Trial Update: Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) [Phase 2]
Phase 2 clinical trial evaluating dosimetry-guided PRRT with 90Y-DOTATOC in neuroendocrine tumors and meningioma; trial completed with resul…
-
EMA withdrawal · 2022-11-16EMA Application withdrawn: Sevsury (surufatinib) — Hutchmed Europe B.V.
The EMA withdrawn the application for Sevsury (surufatinib) by Hutchmed Europe B.V. for neuroendocrine tumors.
-
CLINICAL_TRIALS trial_result · 2022-08-19Clinical Trial Update: An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis [Phase 1, Phase 2]
An open-label pilot study evaluating everolimus with external beam radiotherapy for neuroendocrine tumor liver metastases has completed.
-
CLINICAL_TRIALS trial_result · 2022-06-30Clinical Trial Update: PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105 [Phase 2]
Phase 2 clinical trial updating PET/CT imaging of uPAR-expression in patients with neuroendocrine tumors using 68Ga-NOTA-AE105; study comple…
-
CLINICAL_TRIALS trial_result · 2022-06-30Clinical Trial Update: PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2 [Phase 2]
Phase 2 clinical trial evaluating PET/CT imaging of angiogenesis in neuroendocrine tumor patients using 68Ga-NODAGA-E[c(RGDyK)]2; study stat…
-
FDA approval · 2022-03-23FDA Approved: LOCAMETZ — Original Application (Advanced Accelerator Applications USA, Inc)
The FDA approved LOCAMETZ as an original application for a kit that prepares Gallium-68 gozetotide for PET imaging.
-
FDA approval · 2022-02-09FDA Approved: OCTREOSCAN — Supplemental Application (Curium US LLC)
FDA documents a supplemental approval application for OCTREOSCAN (Indium-111 pentetreotide) submitted by Curium US LLC.
-
CLINICAL_TRIALS trial_result · 2022-02-01Clinical Trial Update: Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors [NA]
Clinical trial update on theranostics using radiolabeled somatostatin antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in neuroendocrine tumor…
-
CLINICAL_TRIALS trial_result · 2022-01-27Clinical Trial Update: Study of Everolimus (RAD001) in Combination With Lenalidomide [Phase 1]
Phase 1 trial evaluating everolimus in combination with lenalidomide for solid organ malignancies and adenoid cystic carcinoma has completed…
-
CLINICAL_TRIALS trial_result · 2022-01-10Clinical Trial Update: 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety [Phase 3]
Phase 3 clinical trial evaluating 18F-DOPA PET imaging for biodistribution and safety.
-
FDA approval · 2021-12-22FDA Approved: NETSPOT — Supplemental Application (Advanced Accelerator Applications USA, Inc)
The FDA approved a supplemental application for NETSPOT (68Ga-DOTATATE) submitted by Advanced Accelerator Applications USA, Inc.
-
FDA approval · 2021-12-17FDA Approved: ILLUCCIX — Original Application (Telix Pharmaceuticals (US) Inc.)
FDA approves the original application for ILLUCCIX, a kit to prepare Gallium-68 gozetotide injection for PET imaging of neuroendocrine tumor…
-
CLINICAL_TRIALS trial_result · 2021-12-14Clinical Trial Update: PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers [Phase 1, Phase 2]
Phase 1/2 trial update for PEN-221 in somatostatin receptor 2 expressing advanced cancers, including neuroendocrine tumors and small cell lu…
-
CLINICAL_TRIALS trial_result · 2021-11-24Clinical Trial Update: Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm [Phase 2]
Phase 2 trial evaluating chidamide plus sintilimab in chemotherapy-refractory advanced high-grade neuroendocrine neoplasm; status not yet de…
-
CLINICAL_TRIALS trial_result · 2021-11-03Clinical Trial Update: Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma [Phase 2]
Phase 2 trial evaluating chidamide with etoposide and cisplatin/carboplatin as first-line therapy for extrapulmonary neuroendocrine carcinom…